Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

February 25, 2026

Conditions

Bioequivalence

Interventions

DRUG

Paclitaxel protein-bound particles for injectable suspension (albumin-bound)

IV infusion, 260 mg/m\^2

DRUG

Abraxane®

IV infusion, 260 mg/m\^2

Trial Locations (1)

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY